What's Happening With These Medical Supplies Stocks? -- Tandem Diabetes Care, Integra LifeSciences, OraSure Technologies, and Insulet

Thursday, February 1, 2018 Diabetes News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Feb. 1, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. 

Today we are offering reports on TNDM, IART, OSUR, and PODD which can be accessed for free by signing up to www.wallstequities.com/registration. Pre-market, WallStEquities.com shifts focus on Tandem Diabetes Care Inc. (NASDAQ: TNDM), Integra LifeSciences
Holdings Corp. (NASDAQ: IART), OraSure Technologies Inc. (NASDAQ: OSUR), and Insulet Corp. (NASDAQ: PODD). These stocks operate in the Medical Instruments and Supplies industry, which primarily researches, develops, and produces nonelectronic medical, surgical, dental, and veterinary instruments and apparatus, such as syringes, anesthesia apparatus, and blood transfusion equipment. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Tandem Diabetes Care

On Wednesday, shares in San Diego, California headquartered Tandem Diabetes Care Inc. rose 1.46%, ending the day at $2.78. The stock recorded a trading volume of 213,020 shares. The Company's shares have advanced 17.80% in the last month and 9.45% over the previous three months. The stock is trading above its 50-day moving average by 2.79%. Moreover, shares of the Company have a Relative Strength Index (RSI) of 47.92.  

On January 08th, 2018, Tandem Diabetes Care reported the successful completion of the first pilot study using a hybrid closed loop system featuring its t:slim X2™ Insulin Pump, with embedded algorithms from TypeZero Technologies and integration with Dexcom® G6 Continuous Glucose Monitoring. The second study is now moving forward with enrollment at seven clinical sites and is anticipated to begin in Q1 2018. Get the full research report on TNDM for free by clicking below at:

www.wallstequities.com/registration/?symbol=TNDM

Integra LifeSciences Holdings

Shares in Plainsboro, New Jersey headquartered Integra LifeSciences Holdings Corp. ended the day 0.30% lower at $52.66 with a total trading volume of 255,938 shares. In the last month and the previous three months, the stock has gained 10.03% and 13.61%, respectively. Additionally, the Company's shares have advanced 26.19% over the past year. The stock is trading above its 50-day and 200-day moving averages by 6.72% and 5.75%, respectively. Furthermore, shares of the Company have an RSI of 63.20. 

On January 05th, 2018, research firm Cantor Fitzgerald resumed its 'Neutral' rating on the Company's stock.

On January 08th, 2018, Integra LifeSciences announced certain unaudited preliminary Q4 2017 financial results. The Company expects reported revenue to be approximately $365 million, and organic revenue growth to be about 5.5%. Q4 2017 adjusted earnings per share, excluding any impact from the Tax Cuts and Jobs Act of 2017, are expected to exceed the high-end of the Company's previous guidance range of $0.53 to $0.57. Today's complimentary research report on IART is accessible at:

www.wallstequities.com/registration/?symbol=IART

OraSure Technologies

At the close of trading on Wednesday, shares in Bethlehem, Pennsylvania-based OraSure Technologies Inc. finished 0.78% lower at $21.76 with a total trading volume of 413,246 shares. The stock has advanced 15.38% in the last month, 8.80% over the previous three months, and 146.71% over the past year. The Company's shares are trading above their 50-day and 200-day moving averages by 17.33% and 20.37%, respectively. Additionally, OraSure Technologies' stock has an RSI of 69.76. 

On January 17th, 2018, OraSure Technologies announced that it will distribute its Q4 2017 financial results on February 07th, 2018, at 4:00 p.m. ET. The Company has scheduled its regular earnings conference call at 5:00 p.m. ET that same day. The conference call will be webcast live and available under the Investor Relations page of the Company's website. Register now for your free research document on OSUR at:

www.wallstequities.com/registration/?symbol=OSUR

Insulet

Billerica, Massachusetts headquartered Insulet Corp.'s shares recorded a trading volume of 296,130 shares at the end of yesterday's session. The stock closed the day 0.93% lower at $76.53. The Company's shares have advanced 10.91% in the past month, 31.18% in the previous three months, and 83.97% over the past year. The stock is trading above its 50-day and 200-day moving averages by 6.73% and 34.02%, respectively. Additionally, shares of Insulet have an RSI of 57.96.  

On January 08th, 2018, research firm Raymond James upgraded the Company's stock rating from 'Market Perform' to 'Outperform'.

On January 29th, 2018, Insulet announced plans to release its Q4 and full-year of 2017 financial results on February 21st, 2018, after the close of the financial markets. In connection with the release, management will host a conference call at 4:30 p.m. ET that day. The live call will be available under the "Events and Presentations" link on the Investor Relations section of the Company's website. Click on the link below and see our free report PODD at:

www.wallstequities.com/registration/?symbol=PODD

--

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: info@wallstequities.com   Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Cision View original content:http://www.prnewswire.com/news-releases/whats-happening-with-these-medical-supplies-stocks----tandem-diabetes-care-integra-lifesciences-orasure-technologies-and-insulet-300591809.html

SOURCE Wall St. Equities



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store